

Amendments to the Claims:

Please amend claims 1-2, 5-6 and 9-10. Please cancel claims 3-4, 7-8 and 21-23. Following entrance of this amendment, claims 1-2, 5-6 and 9-10 will be pending and under consideration. This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1. (Currently amended): A method of ~~preventing and/or~~ treating osteoarthritis in a patient in need thereof comprising orally administering to said patient a pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin in a therapeutically effective amount of a calcitonin in free or salt form and a delivery agent selected from the group of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.

Claim 2. (Currently amended): A method of inhibiting resorption and/or normalizing turnover of subchondral bone in a patient having osteoarthritis or osteoporosis, or in a postmenopausal woman in need thereof comprising orally administering to said patient a pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin therapeutically effective amount of a calcitonin in free or salt form and a delivery agent selected from the group of 5-CNAC, SNAD, SNAC and disodium salts thereof.

Claim 3-4. (Canceled)

Claim 5. (Currently amended): The method according to claim 1, wherein the ~~therapeutically effective amount of a salmon~~ calcitonin is ~~delivered orally in a composition comprising the calcitonin which is conjugated to a polymer molecule.~~

Claim 6. (Currently amended): The method according to claim 1, wherein the ~~therapeutically effective amount of a calcitonin is delivered with an effective dosage of an oral pharmaceutical composition comprising further comprises~~ calcitonin; at least one pharmaceutically acceptable pH-lowering agent, at least one absorption enhancer, and an enteric coating.

Claim 7-8. (Canceled)

Claim 9. (Currently amended): The method according to ~~claim 4~~ claim 6, whereas said pharmaceutical composition comprises a delivery agent selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 10. (Currently amended): The method according to ~~claim 4~~ claim 9, whereas said pharmaceutical composition comprises a delivery agent in micronized form.

Claims 11-16. (Canceled)

Claim 17. (Withdrawn): A pharmaceutical composition for use in the treatment or/and prevention of osteoarthritis in a patient in need thereof, comprising a calcitonin together with one or more pharmaceutically acceptable diluents or carriers therefore.

Claim 18. (Withdrawn): A pharmaceutical combination for use in the treatment or/and prevention of osteoarthritis in a patient thereof, comprising:

- a) a first agent which is a calcitonin, and
- b) a co-agent which is a bone resorption inhibitor, bone forming during or pain reducing agent.

Claim 19. (Withdrawn): A pharmaceutical composition comprising between 0.4 and 2.5 mg of a calcitonin.

Claim 20-23. (Canceled)